Citius Oncology, Inc. CTOR Income Statement
| TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $4.11M-39.8% | $6.17M+22.4% | $6.42M+30.3% | $6.64M+41.6% | $6.83M+47.9% | ||
| $29.7M+175% | $8.32M-16.4% | $8.78M+7.8% | $11.15M+129% | $10.81M+207% | ||
| $48.02M+90.8% | $25.53M+14.1% | $23.52M+14.3% | $25.48M+50.5% | $25.16M+64.1% | ||
| -$43.52M-73.0% | -$22.38M-24.6% | -$23.52M-14.3% | -$25.48M-77.9% | -$25.16M-154% | ||
| $296.9K— | —— | —— | —— | —— | ||
| $1.66M-35.6% | -$153.8K-105% | -$181.66K-105% | $1.9M-3.7% | $2.58M+20.0% | ||
| -$41.95M-66.7% | -$22.58M-0.9% | -$23.7M-15.2% | -$25.64M-51.4% | -$25.16M-64.1% | ||
| $561.51K-31.2% | $1.06M+51.8% | $1.06M+83.5% | $936.72K+62.6% | $816.48K+41.8% | ||
| -$42.51M-63.6% | -$23.64M-2.4% | -$24.76M-17.1% | -$26.58M-87.5% | -$25.98M-196% | ||
| -$0.47-27.0% | -$0.31+6.1% | -$0.34-9.7% | -$0.38-100% | -$0.37-640% | ||
| -$43.52M-73.0% | -$22.38M-24.6% | -$23.52M-14.3% | -$25.48M-77.9% | -$25.16M-154% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Citius Oncology, Inc. profitable?
- Citius Oncology, Inc. is not currently profitable: it reported a net loss of $42.5M over the trailing twelve months.
- What is Citius Oncology, Inc.'s earnings per share?
- Citius Oncology, Inc.'s diluted EPS over the trailing twelve months is $-0.47.
- Where does Citius Oncology, Inc.'s income statement data come from?
- Every line is extracted from Citius Oncology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.